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Abstract
Background: Simple immune capture assays that detect mycobacterial lipoarabinomannan (LAM) antigen in urine
are promising new tools for the diagnosis of HIV-associated tuberculosis (HIV-TB). In addition, however, recent
prospective cohort studies of patients with HIV-TB have demonstrated associations between LAM in the urine and
increased mortality risk during TB treatment, indicating an additional utility of urinary LAM as a prognostic marker.
We conducted a systematic review and meta-analysis to summarise the evidence concerning the strength of this
relationship in adults with HIV-TB in sub-Saharan Africa, thereby quantifying the assay’s prognostic value.
Methods: We searched MEDLINE and Embase databases using comprehensive search terms for ‘HIV’, ‘TB’, ‘LAM’
and ‘sub-Saharan Africa’. Identified studies were reviewed and selected according to predefined criteria.
Results: We identified 10 studies eligible for inclusion in this systematic review, reporting on a total of 1172 HIV-TB
cases. Of these, 512 patients (44 %) tested positive for urinary LAM. After a variable duration of follow-up of
between 2 and 6 months, overall case fatality rates among HIV-TB cases varied between 7 % and 53 %. Pooled
summary estimates generated by random-effects meta-analysis showed a two-fold increased risk of mortality for
urinary LAM-positive HIV-TB cases compared to urinary LAM-negative HIV-TB cases (relative risk 2.3, 95 % confidence
interval 1.6–3.1). Some heterogeneity was explained by study setting and patient population in sub-group analyses.
Five studies also reported multivariable analyses of risk factors for mortality, and pooled summary estimates
demonstrated over two-fold increased mortality risk (odds ratio 2.5, 95 % confidence interval 1.4–4.5) among urinary
LAM-positive HIV-TB cases, even after adjustment for other risk factors for mortality, including CD4 cell count.
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Conclusions: We have demonstrated that detectable LAM in urine is associated with increased risk of mortality
during TB treatment, and that this relationship remains after adjusting for other risk factors for mortality. This may
simply be due to a positive test for urinary LAM serving as a marker of higher mycobacterial load and greater
disease dissemination and severity. Alternatively, LAM antigen may directly compromise host immune responses
through its known immunomodulatory effects. Detectable LAM in the urine is an independent risk factor for
mortality among patients receiving treatment for HIV-TB. Further research is warranted to elucidate the underlying
mechanisms and to determine whether this vulnerable patient population may benefit from adjunctive
interventions.
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Background
Tuberculosis (TB) remains the most frequent cause of
HIV/AIDS-related deaths globally, accounting for 0.4
million deaths in 2014 alone [1]. Diagnosis of HIV-
associated TB (HIV-TB) remains challenging due to
non-specific clinical features, early dissemination beyond
the lungs, the relatively low mycobacterial burden within
sputum samples, and clinical over-reliance on sputum-
based diagnostic tests [2–4]. Mycobacterial culture is
still regarded as the ‘gold standard’ diagnostic test; how-
ever, in practice its use and utility are greatly limited by
prolonged turnaround times and lack of widespread
availability due to the need for expensive infrastructure
and skilled laboratory personnel. Diagnostic tools that
are rapid, have good diagnostic accuracy and can be
used at all levels of the healthcare system will be
required to meet ambitious World Health Organization
(WHO) goals of reducing TB deaths by 95 % and new
cases by 90 % by 2035 [5–7].
Recent years have seen increased investment and
research into rapid, ‘point-of-care’ diagnostics. Given the
challenges of obtaining sputum samples and limited
yield in extrapulmonary TB, urine has been identified as
a favourable alternative biological sample due to the ease
of obtaining samples from patients, the ease of labora-
tory handling and processing, and the lower risk of
nosocomial transmission to healthcare and laboratory
workers. Several mycobacterial antigens have been iden-
tified in the urine of patients with active TB [8, 9].
Promising diagnostic assays to emerge are those that
detect the mycobacterial cell wall lipopolysaccharide
lipoarabinomannan (LAM) using simple immune
capture assays [10]. Testing for LAM in the urine has
proved particularly useful in those with HIV-TB, with
incrementally greater sensitivity with the progression of
immunodeficiency [11–13]. In addition to commercially
available enzyme-linked immunosorbent assays (ELISA),
a simple, low-cost and rapid lateral flow point-of-care
assay has also been developed (Determine TB-LAM;
Alere Inc., Waltham, MA, USA). This is undergoing
impact evaluation as part of the diagnostic algorithms
for HIV-TB in clinical trials in sub-Saharan Africa [14–16],
and WHO have conditionally recommended its use to
assist in TB diagnosis in hospitalised patients with
low (≤100 cells/μl) CD4 cell counts or patients who
are seriously ill [17].
The diagnostic accuracy of urinary LAM detection for
HIV-TB has been extensively studied and is the subject
of a comprehensive Cochrane systematic review and
meta-analysis [18]. However, recent prospective studies
of diagnostic accuracy have also highlighted its prognos-
tic value, demonstrating strong associations between the
detection of urinary LAM and mortality risk during
follow-up on TB treatment; this association persists even
after adjustment for key confounding factors such as
blood CD4 count, blood haemoglobin level and age [19].
Testing for LAM in the urine may therefore be of
additional clinical benefit, over and above the diagnosis
of TB, by identifying patients with the highest mortal-
ity risk who may potentially benefit from closer
follow-up or adjunctive interventions used in combin-
ation with TB treatment, anti-retroviral therapy (ART)
and co-trimoxazole prophylaxis.
We have performed a systematic review and meta-
analysis to summarise the strength of the relationship
between urinary LAM and mortality in adults with
HIV-TB. We also discuss potential mechanisms
underlying these associations and discuss the need for
future research and implications for the implementa-
tion of testing for urinary LAM in this vulnerable
population.
Methods
Search strategy
We searched MEDLINE and Embase databases for
studies reporting urinary LAM status in HIV-infected
adults, and published up until 1 November 2015. The
search strategy involved combining four search ‘sets’
with the Boolean operator ‘AND’. The search sets
included comprehensive terms for ‘tuberculosis’, ‘HIV/
AIDS’ and ‘lipoarabinomannan’, and ‘sub-Saharan Africa’.
References of relevant studies and review articles were
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also searched, and experts in the field contacted to
suggest additional references. The search strategy was
pre-specified in the review protocol (Additional file 1:
Table S1). In addition, abstract books from the Inter-
national Union Against Tuberculosis and Lung Disease
were manually searched, and abstracts from the Confer-
ence of Retroviruses and Opportunistic Infections were
electronically searched (both from 2007 to 2015). The
studies identified were compiled into a database and
screened on title and/or abstract, with duplicates
removed. Full texts of those potentially eligible articles
were reviewed further. This review was conducted and
reported in accordance with the PRISMA checklist [20].
Research ethics permission was not sought because this
was a secondary analysis of published anonymised data.
Study selection
Identified studies were included if they reported mortality
and urinary LAM status in adult patients with HIV-TB
co-infection, if they had at least 10 TB cases with urinary
LAM results and at least five deaths, and if they were
undertaken in sub-Saharan Africa. Studies were excluded
if they did not report mortality outcomes (our primary
outcome of interest), if they related only to paediatric
populations, or if they were studies of particular sub-
populations that were not easily generalisable (e.g., miners
or prisoners). Studies including both HIV-positive and
HIV-negative patients with TB were only included if they
presented disaggregated data based upon HIV status
or if <10 % of the patients with TB were HIV nega-
tive. Non-English-language studies were only included
if adequate data could be extracted from an English
abstract.
Data extraction and analysis
Data were extracted directly into a database by two
reviewers, including study citation, year of publication,
setting (country/healthcare level), number of patients
and TB diagnoses, baseline characteristics, TB reference
standard, method of testing for urinary LAM, number of
LAM-positive and LAM-negative TB cases, mortality in
patients diagnosed with TB (overall and stratified by
urinary LAM status), and risk factors for mortality. The
primary outcome was the risk of mortality in urinary
LAM-positive TB cases compared to LAM-negative TB
cases. Case fatality rates were calculated based on total
number of TB cases with follow-up data and total
number of deaths. The other outcome of interest was
adjusted odds ratio (OR) of mortality for urinary LAM-
positive TB cases (based on a multivariable analysis
including other predictors of mortality). Studies were
included in the analysis if these data were presented. If
adjusted OR of death was not presented, the author was
contacted to ask if those data were available. Study
quality was graded according to a pre-specified checklist,
which was adapted from the QUADAS-2 tool (see
Additional file 1: Table S2) [21].
All analyses was done using Stata 11.0 (StataCorp,
College Station, TX, USA) and were done on study-level
data. Forest plots were generated for mortality risk ratio.
The heterogeneity of study outcomes were calculated
using the I2 statistic. Pooled estimates were calculated
using random-effects modelling, with study weights
assigned based on inverse variance. The source of
heterogeneity was explored using sub-group analyses
(study setting, median CD4 cell count, overall TB
mortality, time at which mortality outcome was
measured). A fixed continuity correction of 0.5 was used
for studies with 0 or 100 % mortality in any group. The
adjusted ORs for mortality from multivariate regression
analyses were also presented in a forest plot and sum-
mary statistics calculated as above. Funnel plots of log
ORs against their standard error and Egger’s test were
used to aid assessment of bias.
Results
A total of 161 citations were identified, 49 studies
selected for full-text review, and 10 studies eligible for
inclusion (Fig. 1). Included studies are summarized in
Table 1. All studies were cohort in design, conducted in
sub-Saharan Africa, enrolled adults ≥18 years of age, and
reported between 2009 and 2015. Three studies were
based in an outpatient setting, six were of hospital inpa-
tients, and one enrolled patients from both settings.
Most studies enrolled patients in whom TB was the
suspected diagnosis based on clinical presentation,
although three studies were done in patients due to start
ART, and one study was restricted to patients with a TB
diagnosis (Table 1). Two studies reported results in
HIV-positive and HIV-negative patients. These were
eligible for inclusion in this review because the number
of HIV-negative cases comprised <10 % of the total TB
cases. Eight studies used the Determine TB-LAM lat-
eral flow assay to test for urinary LAM, and two studies
used the Clearview TB ELISA (Inverness Medical Inno-
vations, UK). All studies used standard first-line TB
treatment and initiated ART in accordance with na-
tional guidelines at the time. This review includes data
from 1172 TB cases and 512 (44 %) urinary LAM-
positive cases in total. Five studies were deemed as
being of good quality, and five of moderate quality
(Table 1).
The proportion of urinary LAM-positive TB cases
varied from 22 % to 65 %, and was higher in studies of
hospital inpatients than those of outpatients (mean 49 %
and 30 % respectively, P = 0.04). Nine of the studies used
microbiological definitions of TB cases, which included
mycobacterial culture and/or the Xpert MTB/RIF assay
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(Cepheid, Sunnyvale, CA, USA). Three studies included
only sputum samples in the reference standard, and six
included at least one non-respiratory sample within the
reference standard for TB diagnosis. Of the eight studies
using the TB-LAM assay, four used the grade 2 cut-off
as a ‘positive’ result, two used a grade 1 or higher
cut-off, and two did not report which cut-off was
used (Additional file 1: Table S3). Median loss to
follow-up was 13.4 % (range 0–43 %, Additional file 1:
Table S3).
Mortality outcomes in TB cases were assessed at
between 2 and 3 months of follow-up for six studies,
at 6 months in three studies, and at 36 months in
one study. Overall case fatality rates among HIV-TB
cases varied between 7 % and 53 %. Median CD4 cell
counts varied between 57 and 210 cell/mm3 (overall
median 114 cells/mm3), indicating severely immuno-
compromised patient populations. Loss to follow-up
rates varied greatly between studies (Additional file 1:
Table S3).
All studies demonstrated an increased risk of mortal-
ity amongst urinary LAM-positive TB cases compared
to LAM-negative cases, with the relative risk (RR)
of mortality varying from 1.2 to 7.5 (median 2.5, inter-
quartile rate 1.8–3.4; Table 1, Fig. 2). A pooled
summary estimate generated using a random-effects
meta-analysis showed a two-fold increased risk of mor-
tality (RR 2.3, 95 % confidence interval [CI] 1.6–3.1;
Fig. 2), but demonstrated moderate heterogeneity (I2 =
37.0 %, P = 0.113).
Sub-group analyses were undertaken to try to explain
the heterogeneity in mortality risk across studies
(Additional file 1: Table S4). Stratifying studies by
healthcare setting removed heterogeneity amongst
studies conducted on hospitalised patients, giving a
pooled summary RR for mortality of 1.9 (95 % CI 1.5–
2.5; Fig. 2). The summary RR of mortality was higher at
3.4 (95 % CI 1.2–9.5, n = 4) for outpatient studies, but
showed greater variation (I2 = 69.2 %). A similar effect
was seen in sub-group analysis by overall TB mortality,
with an almost two-fold increase in mortality risk as-
sociated with LAM-positivity when overall mortality
was >20 % (RR 1.8, 95 % CI 1.4–2.2, n = 5). Studies
with overall mortality risk ≤20 % showed an even
greater RR of mortality for LAM-positive patients (RR
3.7, 95 % CI 2.2–6.2, n = 5). Studies with a median
CD4 cell count >100 cells/μl had a higher RR for
mortality in LAM-positive patients than those with
medians ≤100 cells/μl (RR 2.7, 95 % CI 1.5–4.7, n = 5
and RR 1.9, 95 % CI 1.4–2.6, n = 5 respectively). The
Fig. 1 Flow chart showing study selection process. LAM lipoarabinomannan
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Table 1 Studies reporting urinary LAM detection and mortality included in the systematic review
Study LAM assay used
(type of urine
sample)
Study setting
and population
(country)
Median CD4 cell
count (by LAM
status if presented)
(cells/μl)
Number of TB
cases/total
number in study
(prevalence %)
Number of urinary
LAM-positive TB
cases (%)
Duration of
follow-up
(months)
Overall
mortality
in TB
cases (%)
Number of TB
deaths/number
of TB cases (%)
RR of mortalitya
(95 % CI)
Quality
assessment
scoreb
LAM positive LAM negative
Shah et al.
(2009) [47]
Clearview TB ELISA
(frozen urine)
Hospitalised patients;
TB suspected (South
Africa)
79 193/499 (38.7) 114 (59.1) 2 22.3 31/114 (27.2) 12/79 (15.2) 1.8 (1.0–3.3) 60
Lawn et al.
(2012) [48]
Determine TB-LAM
lateral flow assay
(frozen urine)
Outpatient clinic;
patients initiating
ART (South Africa)
100 (LAM-positive
37; LAM-negative
115)
59/325 (18.2) 23 (39.0) 3 8.5 5/23 (21.7) 0/36 (0.0) NA 70
Talbot et al.
(2012) [49]
Clearview TB ELISA
(fresh and frozen
urine)
Hospitalised patients;
TB suspected
(Tanzania)
86 69/212 (32.5) 45 (65.2) 2 52.9 25/38 (65.8) 33/83 (39.8) 1.7 (1.2–2.3) 75
Peter et al.
(2013) [50]
Determine TB-LAM
lateral flow assay
(frozen urine)
Hospitalised patients;
TB suspected
(South Africa)
89 (LAM-positive
62; LAM-negative
180)
116/281 (4.2) 58 (50.0) 2 13.9 6/25 (24.0)c 1/23 (8.5)c 5.5 (0.7–42.4) 80
Balcha et al.
(2014) [51]
Determine TB-LAM
lateral flow assay
(frozen urine)
Outpatient clinic;
ART naïve; sputum
producers (Ethiopia)
176 (LAM-positive
94; LAM-negative
187)
128/757 (16.9) 35 (27.3) 6 6.8 7/35 (20.0) 3/113 (2.7) 7.5 (2.1–27.6) 60
Manabe
et al. (2014)
[28]
Determine TB-LAM
lateral flow assay
(fresh urine)
Hospitalised patients;
TB suspects (Uganda)
57 145/351 (41.3) 90 (62.1) 2 22.1 25/90 (27.8) 7/37 (12.7) 2.2 (1.0–4.7) 75
Drain et al.
(2015) [52]
Determine TB-LAM
lateral flow assay
(frozen urine)
Outpatient clinic;
patients initiating
TB treatment
(South Africa)
168 (LAM-positive
106; LAM-negative
198)
90/90 (100.0) 29 (22.2) 36 27.8 9/29 (31.0) 16/61 (26.2) 1.2 (0.6–2.4) 70
Peter et al.
(2015) [53]
Determine TB-LAM
lateral flow assay
(frozen urine)
Hospitalised patients;
TB suspected
(South Africa)
210 181/583 (31.0) 41 (22.7) 6 13.0 6/17 (35.2) 15/106 (14.2) 2.5 (1.1–5.5) 85
Lawn et al.
(2015) [54]
Determine TB-LAM
lateral flow assay
(frozen urine)
Hospitalised patients;
all HIV+ patients
(South Africa)
148 136/427 (31.2) 53 (39.0) 3 13.7 13/5 (24.5) 6/83 (7.2) 3.4 (1.4–8.4) 75
Bjerrum et al.
(2015) [55]
Determine TB-LAM
lateral flow assay
(fresh urine)
Hospital inpatient
and outpatient;
TB suspected (Ghana)
127 55/469 (11.7) 24 (43.6) 6 32.7 13/24 (54.2) 5/31 (16.1) 3.4 (1.4–8.1) 70
ART antiretroviral therapy, CI confidence interval, ELISA enzyme-linked immunosorbent assay, LAM lipoarabinomannan, NA not applicable, RR relative risk, TB tuberculosis. aUrinary LAM-positive TB cases compared to
urinary LAM-negative TB cases. bQuality assessment score graded as follows: (<50 poor, 50–74 moderate, >74 good. cMortality in TB cases with urinary LAM results only reported in patients who did not receive ‘early
empirical TB therapy’
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summary RRs were similar when studies were stra-
tified by time at which mortality was measured
(≤3 months RR 2.1, 95 % CI 1.5–2.9, n = 6; >3 months
RR 2.6, 95 % CI 1.3–5.2).
Sensitivity analyses showed that excluding the two
studies reporting a small number of HIV-negative cases
(<1 % of total TB cases included in the meta-analysis)
did not alter the overall effect size. Further sensitivity
analyses excluding studies using a (pre-January 2014)
grade 1 cut-off for TB-LAM or not reporting cut-off
grade, studies using the Clearview TB-ELISA and not
the TB-LAM assay, studies with only respiratory samples
in the TB reference standard, studies of low or moderate
quality, and studies with >20 % loss to follow-up also
resulted in no substantial change in the overall effect
size. Analyses with little heterogeneity were also re-
peated using fixed-effects meta-analysis, which did not
alter the effect size (data not shown). A funnel plot
showed few studies with small or no effect size, which
may suggest publication bias (Egger’s test P = 0.025;
Additional file 1: Figure S1).
Five studies reported results of multivariable regres-
sion analyses for mortality, including urinary LAM de-
tection as a variable. No studies were powered to detect
a difference in mortality by urinary LAM status, but
three studies demonstrated urinary LAM was an inde-
pendent predictor for mortality (adjusted OR varied
from 2.2 to 4.7). Risk factors included in multivariable
.
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b
Fig. 2 Forest plot showing relative risk (RR) of mortality in urinary lipoarabinomannan (LAM)-positive tuberculosis (TB) cases compared to urinary
LAM-negative TB cases, stratified by (a) study setting and (b) overall mortality in patients with TB
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models are outlined in Table 2 and included CD4 cell
count (as a marker of HIV-associated immunosuppres-
sion) in four studies. A pooled summary estimate calcu-
lated using meta-analysis showed an over two-fold
increased odds of mortality (OR 2.5, 95 % CI 1.4–4.5;
Fig. 3) among HIV-TB cases with positive urinary LAM
tests, even after adjustment for other risk factors for
mortality. However, these studies did show a large degree
of heterogeneity in their effect sizes. Studies in which
overall mortality was ≤20 % had a greater summary RR for
mortality in LAM-positive patients (RR 4.4, 95 % CI 2.1–
9.5) compared to studies with a mortality >20 % (1.9, 95 %
CI 1.1–3.3; Fig. 3), although there were few studies in each
sub-group and CIs overlapped.
Discussion
This is the first systematic review and meta-analysis to
assess the association between urinary LAM detection
and mortality during TB treatment in patients with
HIV-TB. The meta-analysis demonstrated a two-fold
greater mortality risk among those patients with urinary
LAM-positive compared to urinary LAM-negative TB.
Five studies reported adjusted OR of mortality in LAM-
positive TB cases, and demonstrated that urinary LAM
is an independent predictor of mortality in TB cases,
even after adjustment for other important risk factors
for mortality, such as degree of immunosuppression.
There are multiple potential mechanisms that may
underlie this association (Table 3).
The strengths of this systematic review and meta-
analysis include the synthesis of data from a large
number of patients enrolled in studies in diverse settings
across sub-Saharan Africa, with data from 1172 patients
with TB, of whom 44 % had LAM detected in their
urine. The selection of patients was well described in all
studies, and was mostly representative of the population
for which urinary LAM testing has been conditionally
recommended in recent WHO policy guidance (patients
suspected of having TB, HIV-positive patients with low
CD4 cell counts, or seriously unwell patients such as
those requiring hospitalisation) [17]. Studies were not
powered to demonstrate a mortality difference based on
urinary LAM detection, but the meta-analysis has
demonstrated a robust association.
Although there effect size varied across studies, het-
erogeneity appeared to be moderate at most (I2 = 39 %).
The most likely sources of variation were in the settings
and patient populations. Studies conducted in hospital
settings, which had higher overall TB mortality and
lower median CD4 cell counts, showed approximately
double the mortality risk in LAM-positive compared to
LAM-negative TB patients. Surprisingly, the association
between LAM-positivity and mortality was even stronger
in outpatient settings, with lower overall TB mortality
and higher median CD4 cell counts, although effect sizes
were more variable. Urinary LAM testing may be an even
better marker of poor prognosis in these settings, although
recent WHO recommendations do not specify its use as
diagnostic for TB in these patient populations [17].
Limitations of this systematic review include the
over-representation of South Africa amongst the study
settings, which is true for HIV-TB research as a
whole. Different methods of detecting LAM in urine were
used, as were different cut-offs for the Determine TB-
LAM lateral flow assay. In addition, although most studies
used mycobacterial culture from sputum as the reference
standard for diagnosing TB, there was some variation in
case definitions for HIV-TB. Although two eligible studies
included a very small number of HIV-negative cases, their
exclusion in a sensitivity analysis did not impact the
overall effect size. All studies were deemed of moder-
ate or good quality. Sensitivity analyses demonstrated
that none of the above issues substantially altered the
overall effect size.
There were some potential sources of bias in this study.
Three studies reported high rates of loss to follow-up
Table 2 Studies reporting adjusted odds ratios for mortality in urinary LAM-positive compared to urinary LAM-negative TB cases,
after adjustment for other predictors of mortality
Study Study setting and population Adjusted odds ratio for mortality in urinary
LAM-positive compared to urinary
LAM-negative TB cases (95 % CI)
Variables included in the multivariable
analysis with urinary LAM status
Talbot et al. (2012) [49] Hospital inpatients;
TB suspected
1.3 (0.9–1.8) CD4 cell count, ART
Drain et al. (2015) [52] Outpatients; confirmed
TB patients
5 (1.1–23.9) CD4 cell count, age, gender,
Karnofsky score
Peter et al. (2015) [53] Hospital inpatients;
TB suspected
4.7 (1.6–15.9) Study site, gender, age,
CD4 cell count
Lawn et al. (2015) [54] Hospital inpatients;
All HIV+ patients
4.2 (1.5–11.8) Age, CD4 cell count
Bjerrum et al. (2015) [55] Hospital inpatients and
outpatients; TB suspected
2.2 (1.1–3.5) Gender, hospitalisation, CD4 cell
count, Medical Early Warning Score
ART antiretroviral therapy, CI confidence interval, LAM lipoarabinomannan, TB tuberculosis
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(>20 %), which may have included a disproportionate
number of unascertained deaths, especially if patients that
died later were more likely to be LAM-negative. A sensi-
tivity analysis showed that excluding studies with high loss
to follow-up did not alter effect size. Many studies were
excluded from the systematic review because they did not
report mortality rates, and assessment for publication bias
revealed a lack of smaller studies demonstrating small,
weak associations or no association at all. Most studies
reporting urinary LAM testing in HIV-TB co-infection
were studies on diagnostic accuracy. It is likely that the
majority of these did not gather mortality data, and studies
included in this review mostly reported mortality as a
secondary outcome. Finally, only five studies reported
adjusted multivariable models for mortality that included
urinary LAM detection as a variable, making exploration
of heterogeneity by sub-group analysis challenging.
The mechanism by which LAM enters the urine has
been an issue of contention, with early literature assuming
LAM antigenuria resulted from free renal glomerular fil-
tration of circulating LAM from the bloodstream [22, 23].
However, some researchers had also speculated that
haematogenous dissemination of TB resulted in renal
involvement and direct shedding into the urine, and this
Fig. 3 Forest plot showing adjusted odds ratio of mortality in urinary lipoarabinomannan (LAM)-positive tuberculosis (TB) cases compared to
urinary LAM-negative TB cases, stratified by overall mortality in TB cases. CI confidence interval, OR odds ratio
Table 3 Potential mechanisms of the association between urinary LAM detection and increased mortality risk
Potential mechanism Evidence References
Urinary LAM is a marker of disseminated
TB and higher mycobacterial burden,
which is associated with a worse prognosis
• Urinary LAM is due to haematogenously
disseminated renal TB
Cox et al. 2015 [26]
• HIV-TB patients with mycobacteraemia have
a higher mortality
Cummings et al. 2015 [56]
• Higher concentrations of urinary LAM are
associated with higher mycobacterial burden
Kerkhoff et al. 2014 [19]
Urinary LAM is a proxy for a low CD4 cell count • HIV-TB patients with positive urinary LAM
tests have lower CD4 cell counts
Minion et al. 2011 [11]
• Mortality is higher in patients with lower
CD4 cell counts
Gupta et al. 2015 [34]
LAM itself contributes to immunosuppression,
impairing host defences against MTB and
other opportunistic infections
• LAM is a virulence factor for MTB Strohmeier et al. 1999 [35]
• LAM inhibits immune responses, with direct
inhibitory effects on macrophage activation
and function
Mishra et al. 2011 [38] Neyrolles et al. 2011 [41]
• LAM inhibits pro-inflammatory cytokines,
e.g. IL-12 and TNF-α
• LAM enhances the secretion of anti-inflammatory
cytokines, e.g. IL-10
LAM lipoarabinomannan, MTB Mycobacterium tuberculosis, TB tuberculosis
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mechanism has now been demonstrated beyond doubt by
multiple lines of evidence, including post-mortem data
[24–27]. Moreover, urinary LAM has also been associated
with mycobacteraemia and other markers of higher myco-
bacterial burden [19, 28–31]. Therefore, urinary LAM
may simply be a marker of more severe, disseminated TB,
explaining its association with mortality. Early studies
of urinary LAM detection in patients with HIV-TB
co-infection also demonstrated an association with TB
immune reconstitution inflammatory syndrome (IRIS)
[32], although this is unlikely to be an important a cause
of increased mortality because TB-IRIS is rarely fatal [33].
Urinary LAM assays are also more sensitive in
patients with lower CD4 cell counts (typically <100
cells/μl) [11, 25], because these patients have the
highest risk of disseminated and renal TB. However,
these are the very patients with the highest mortality
risk [34], and therefore the higher mortality risk
associated with urinary LAM detection may be con-
founded by CD4 cell count. However, of particular
note, we have demonstrated in this meta-analysis that,
even after adjusting for CD4 cell count as well as
other predictors of mortality, urinary LAM remains
an independent marker of mortality. Although mortal-
ity in LAM-negative TB cases is lower than that in
LAM-positive cases, it was still up to 40 % in some
studies. Without post-mortem data, it is difficult to
attribute cause of death to TB or other co-infection
or pathologies.
LAM itself may be on the causal pathway leading to
increased mortality risk. Much in vitro research has
examined the role of LAM as a virulence factor for
Mycobacterium tuberculosis (MTB) [35]. LAM is a
19 kDa glycolipid and is a major constituent of MTB
and the mycobacterial cell wall. It binds to several cell
surface receptors of the immune system, especially mac-
rophages [36, 37]. Through its immunomodulatory
effects, LAM is thought to promote the survival of MTB
in the human host [38] by directly impairing host
immune defences. Its immunological effects include
inhibition of cytokines that are key in the host immune
response to MTB, such as interleukin (IL)-12, tissue
necrosis factor alpha (TNF-α) and other inflammatory
mediators [39–41]. Furthermore, LAM has been shown
to enhance the secretion of anti-inflammatory cytokines
such as IL-10 [42, 43]. LAM contributes to increased
survival of MTB in macrophages, employing mecha-
nisms that include prevention of macrophage phago-
some maturation [44, 45]. These immunosuppressive
effects of LAM could impair host responses to MTB and
also to other opportunistic infections, and thereby
contribute to increased mortality risk amongst patients
who test positive for urinary LAM. In contrast, non-
pathogenic mycobacteria contain structurally different
LAM molecules to MTB that promote strong pro-
inflammatory responses [38, 46].
The diagnostic utility of urinary LAM assays appears
to be limited to HIV-positive patients with advanced
immunosuppression. It is important to note that whilst
we have found that patients with LAM detected in their
urine had a higher mortality risk from the point of diag-
nosis and commencing anti-TB treatment, it is plausible
that the use of urinary LAM assays to expedite the
diagnosis and treatment of TB can also reduce mortality.
This hypothesis and the impact of urinary LAM assays
as a diagnostic tool in HIV-TB are currently being
evaluated [14–16].
However, these assays identify patients at significantly
increased risk of mortality during follow-up on TB treat-
ment, above and beyond that accounted for by advanced
immunosuppression and TB diagnosis. This appears to
be true even in populations in which urinary LAM test-
ing is not recommended for diagnostic purposes. This
finding should prompt further research into whether
interventions, in addition to the timely initiation of anti-
TB therapy and ART, might benefit these patients and
reduce their high mortality risk. Given the potential
immunosuppressive nature of LAM itself, research is
warranted to explore whether patients who are LAM-
positive have altered immune responses compared to
those who are LAM negative. Potential adjunctive inter-
ventions for these patients might be needed.
Conclusions
This systematic review and meta-analysis has shown that
patients with HIV-TB and detectable urinary LAM have
increased mortality risk compared to those patients with
TB without detectable urinary LAM. Urinary LAM is an
independent risk factor for mortality, suggesting this find-
ing is not simply an epiphenomenon detecting patients
with more advanced immunosuppression. We have pre-
sented several plausible biological explanations for this
association, including LAM’s immunosuppressive effects
in vitro. Urinary LAM detection appears to be a feasible
tool to highlight patients at high risk of mortality as well as
identifying potential targets for adjunctive therapeutic in-
terventions for reducing TB deaths over the next 20 years.
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